Check Capital Management Inc. CA Acquires 75 Shares of Amgen Inc. (NASDAQ:AMGN)

Check Capital Management Inc. CA increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 2.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,795 shares of the medical research company’s stock after acquiring an additional 75 shares during the period. Amgen comprises about 0.0% of Check Capital Management Inc. CA’s investment portfolio, making the stock its 21st biggest position. Check Capital Management Inc. CA’s holdings in Amgen were worth $1,223,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Capital Performance Advisors LLP acquired a new stake in Amgen during the third quarter valued at approximately $25,000. Strategic Financial Concepts LLC acquired a new stake in Amgen in the 2nd quarter valued at $26,000. Hershey Financial Advisers LLC acquired a new stake in Amgen in the 2nd quarter valued at $30,000. nVerses Capital LLC bought a new stake in Amgen in the second quarter valued at $31,000. Finally, Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen in the 2nd quarter valued at $33,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 1.8 %

NASDAQ:AMGN opened at $295.93 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 12-month low of $260.52 and a 12-month high of $346.85. The stock’s fifty day simple moving average is $322.15 and its 200-day simple moving average is $318.15. The firm has a market capitalization of $159.07 billion, a P/E ratio of 37.89, a P/E/G ratio of 2.69 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company’s revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the business earned $4.96 earnings per share. Equities research analysts expect that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.04%. Amgen’s dividend payout ratio is 115.24%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AMGN. Truist Financial cut shares of Amgen from a “buy” rating to a “hold” rating and increased their target price for the stock from $320.00 to $333.00 in a research report on Monday, October 14th. Robert W. Baird reaffirmed an “underperform” rating and set a $215.00 price objective on shares of Amgen in a report on Wednesday, September 25th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $305.00 price target (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Sanford C. Bernstein began coverage on Amgen in a research report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price objective for the company. Finally, Jefferies Financial Group restated a “buy” rating and set a $380.00 target price on shares of Amgen in a report on Tuesday. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and an average price target of $333.57.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.